- Home
- GSK vs SNY Comparison
GSK vs SNY Comparison
Compare GSK & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GSK | SNY |
|---|---|---|
| Founded | 1715 | 1994 |
| Country | United Kingdom | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.0B | 119.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GSK | SNY |
|---|---|---|
| Price | $50.80 | $47.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | N/A | ★ $61.50 |
| AVG Volume (30 Days) | ★ 3.4M | 2.8M |
| Earning Date | 02-04-2026 | 01-29-2026 |
| Dividend Yield | 3.36% | ★ 3.39% |
| EPS Growth | ★ 118.57 | 105.93 |
| EPS | 1.79 | ★ 8.67 |
| Revenue | $43,237,357,842.00 | ★ $53,890,648,839.00 |
| Revenue This Year | $6.70 | $1.73 |
| Revenue Next Year | $5.10 | $6.49 |
| P/E Ratio | $27.94 | ★ $5.44 |
| Revenue Growth | ★ 2.73 | N/A |
| 52 Week Low | $31.72 | $44.62 |
| 52 Week High | $51.46 | $60.12 |
Technical Indicators
Market Signals| Indicator | GSK | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 64.62 | 46.30 |
| Support Level | $49.32 | $46.68 |
| Resistance Level | $50.82 | $49.34 |
| Average True Range (ATR) | 0.62 | 0.64 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 77.57 | 46.72 |
Price Performance
Historical ComparisonAbout GSK GSK plc (Each representing two)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.